| Theme | Autoimmune Diseases in Gastroenterology | |
|---|---|---|
| Title | Inflammatory Bowel Disease as an Autoimmune Disease | |
| Publish Date | 2003/12 | |
| Author | Takayuki Matsumoto | Department of Gastroenterology, Graduate School of Medicine, Osaka City University |
| Author | Yoshio Jinno | Department of Gastroenterology, Graduate School of Medicine, Osaka City University |
| Author | Kenji Watanabe | Department of Gastroenterology, Graduate School of Medicine, Osaka City University |
| Author | Jun-ichi Hara | Department of Internal Medicine, Fuchu Hospital |
| Author | Shiro Nakamura | Department of Gastroenterology, Graduate School of Medicine, Osaka City University |
| Author | Nobuhide Oshitani | Department of Gastroenterology, Graduate School of Medicine, Osaka City University |
| Author | Yoshihisa Watanabe | Center of Gastroenterology, Higashi-sumiyoshi Morimoto Hospital |
| Author | Atsuo Kitano | Center of Gastroenterology, Higashi-sumiyoshi Morimoto Hospital |
| Author | Yasuhiro Fujiwara | Department of Gastroenterology, Graduate School of Medicine, Osaka City University |
| Author | Kazuhide Higuchi | Department of Gastroenterology, Graduate School of Medicine, Osaka City University |
| Author | Tetsuo Arakawa | Department of Gastroenterology, Graduate School of Medicine, Osaka City University |
| [ Summary ] | Ulcerative colitis and Crohn's disease are chronic refractory inflammatory diseases of the intestine and are often associated with impaired immune reactions. Ulcerative colitis is especially often associated with serum autoantibodies, such as anti-colon antibodies, anti-tropomyosin antibodies and anti-goblet cell antibodies. However, humoral autoantibody production has not been revealed in patients with Crohn's disease. In the differential diagnosis of ulcerative colitis and Crohn's disease, pANCA is associated with certain types of ulcerative colitis, while positive serum ASCA levels are related to Crohn's disease. As background genetic abnormalities, several types of HLA-DR associated changes have been reported in ulcerative colitis, while association with genotypic predisposition in TNF, TNF-alpha receptors and NOD2, an important cytoplasmic receptor for bacterial LPS, have been clarified in Crohn's disease. Based on the above findings, anti-TNF-alpha antibodies and anti-IL-6 receptor antibodies are used as powerful tools for inducing remission in patients with active and intractable Crohn's disease, either with external fistula or without fistula. |
|